Tyra Biosciences, Inc.

NASDAQ:TYRA

Biotechnology

Healthcare
$19.61 -2.48%

-$0.72 today

Market cap
$1.35B
Beta
0.75
P/E (TTM)
-13.4
EPS (TTM)
-$2.12
52W Low $8.98High $40.65

Volume 0.47M

Average 0.96M

TYRA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Tyra Biosciences, Inc.NASDAQ: TYRA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $41.86M rose 31.4% year over year, ahead of the +25.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at +31.1% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +31.4% holds above the trailing-twelve-month pace of +25.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$41.86M+14.6% QoQ
Last fiscal yearDec 2025
$132.76M+27.4% YoY
LTMMar 2026
$142.77M+25.7% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.4%——
1 year+27.4%——
3-year CAGR+31.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
132.76M USD
Year-over-year change
+27.4%
4-year CAGR
+49.9%

Operating Expenses vs competitors

How TYRA compares with its peers on the latest reported figures

  • TYRA's LTM Mar 2026 operating expenses of $142.77M is the 10th highest of the 11 companies compared; the peer median is $173.79M.
  • Its year-over-year change of +25.7% is the 6th highest of 11, against a peer median of +22.6%.
  • Over three fiscal years its annual growth of +31.1% compares with a peer median of +30.7%.
TYRA Competitors Peer median
Operating Expenses for TYRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$385.56M +42.1%+38.4%538.2%
NUVBNuvation Bio Inc.LTM Jun 2026$297.23M +30.0%+30.7%174.9%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$240.35M +15.1%——
VSTMVerastem, Inc.LTM Mar 2026$212.38M +50.5%+37.4%428.3%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$174.06M +60.0%+60.5%—
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M -10.6%-12.1%110.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$168.69M +127.4%+30.3%780.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$156.87M +11.7%+68.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$149.59M +2.2%+15.6%—
TYRATyra Biosciences, Inc.LTM Mar 2026$142.77M +25.7%+31.1%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.05M -28.0%-7.0%308.4%
Peer median (excluding TYRA) $173.79M+22.6%+30.7%368.4%

Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development20.64M43.01M62.52M80.08M102.93M
Selling, General & Admin5.65M15.92M17.43M24.1M29.83M
Operating Expenses26.29M58.93M79.95M104.18M132.76M
Depreciation & Amortization140K296K357K519K546K
EBITDA(26.15M)(55.03M)(68.78M)(85.96M)(119.4M)
EBITDA Margin—————
Operating Income(26.29M)(58.93M)(79.95M)(104.18M)(132.76M)
Operating Margin—————
Interest Income13K3.65M10.81M17.7M12.82M
Interest Expense00000
Other Income / Expenses(6K)3.6M10.81M17.7M12.82M
Income Before Tax(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(26.29M)(55.33M)(69.13M)(86.48M)(119.95M)
Net Margin—————
EPS (Basic)(0.63)(1.23)(1.62)(1.51)(2.01)
EPS (Diluted)(0.63)(1.23)(1.62)(1.51)(2.01)
Weighted Avg Shares41.44M41.88M42.7M57.22M59.6M
Weighted Avg Shares (Diluted)41.44M41.88M42.7M57.22M59.6M

Tyra Biosciences, Inc.

NASDAQ:TYRA

Intrinsic Alpha fair value

Locked

Current Price

$19.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.